- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00763919
Customized Medication Adherence Enhancement for Treating Adults With Bipolar Disorder
Customized Adherence Enhancement in Bipolar Disorder (CAE in BD)
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Bipolar disorder (BPD) is a chronic disorder characterized by manic and depressive episodes that disrupt healthy, functional lives. Despite recent advances in medication treatments, many BPD patients do not take their medications. Medication nonadherence is associated with multiple risks, such as relapse, rehospitalization, lengthier hospital stays, and, in some cases, increased risk of suicide. Some studies have shown that treatment adherence in BPD can be improved, particularly through psychological education, development of self-management strategies or behaviors, and ongoing relapse prevention.
This study will examine the effectiveness of medication adherence treatment modules specialized to deal with specific reasons for nonadherence. Participants, all of whom have a history of medication nonadherence, will undergo structured interviews and complete self-report questionnaires to determine individual reasons for nonadherence. Based on their individual profiles, participants will be assigned to one or more of the following intervention modules:
- Psychoeducation: This module uses education about BPD and related treatment to address patient issues such as opposition to preventive efforts, denial of the need for or effectiveness of medication, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment related to BPD treatment.
- Substance abuse: This module targets substance abuse problems that interfere with medication adherence.
- Communication with providers: This module addresses fear of medication side effects by improving communication with health care providers.
- Medication routines management: This module addresses difficulties establishing a medication routine and outside opposition to medications by developing strategies for consistent medication adherence routines.
Each module will involve four 60-minute sessions conducted in a 4- to 6-week period. The study therapist will conduct each of these sessions individually with the participant, combining or coadministering modules in a single session if participants are assigned to more than one module. Depending on which module or modules participants are assigned to, they may also be contacted by phone one to three times by the therapist to complete all module materials.
This study will be conducted in two phases. In the first, an initial group of participants will undergo the module treatments and then participants and therapists will be interviewed about the effectiveness and feasibility of the interventions. This feedback will be used to refine the modules. In the second phase, a second group of participants will undergo treatment in the refined modules and provide more feedback. All participants will continue with their regular treatment while undergoing module treatments.
Participation in this study will last 4 to 6 weeks, with follow-up interviews and assessments ending 6 months after completion of the intervention. In all, there will be five assessments, completed at an initial screening visit, just before treatment, just after treatment, and 3 and 6 months after the completion of treatment. The initial assessments will last 60 to 90 minutes and involve questionnaires and a structured interview. The other four assessments will last 45 to 60 minutes. Treatment adherence, attitudes toward medications, BPD symptoms, and overall functioning will be measured at each assessment. The number of pills used in each participant's prescription bottles will also be counted as a measure of medication adherence.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44122
- Connections
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Clinical diagnosis of bipolar disorder (BPD) Type I or Type II, as determined by a standardized diagnostic interview, the Mini-International Neuropsychiatric Interview (MINI)
- Demonstrated history of poor medication adherence, as determined by self-report or clinician report. In this study, self-reported treatment nonadherence will be identified with the Tablet Routines Questionnaire (TRQ). Poorly adherent individuals will be defined as those who miss 30% or more of medication within either the past week or past month (those missing 30% or more within past week will be considered to be nonadherent over the past month). Clinician-assessed nonadherence will be identified via a clinician version of the TRQ to identify nonadherence of 30% or more over the past 30 days.
- BPD of at least 2 years' duration
- Treatment with medication to stabilize mood for at least 6 months
Exclusion Criteria:
- Unable/unwilling to participate in psychiatric interviews, as based on the clinical opinion of the investigator or the treating clinician
- High risk of suicide, as seen in factors such as active suicidal ideation, recent suicide attempt, or current intent or plan
- Inability to speak English
- Individuals who have participated in Project 1, Personal Adherence Evaluation of Individuals Receiving Treatment for Bipolar Disorder (PAE in BD)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Customized Adherence Enhancement (CAE)
Participants, all of whom have a history of medication nonadherence, will be assigned to one or more treatment modules based on their individual profiles. Treatment Modules: Psychoeducation module Substance abuse module Improved communication/rapport with provider module Medication routines management module |
The psychoeducation module will use psychological and medication education to address opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments.
The substance abuse module will address problematic substance abuse, particularly as it relates to medication adherence.
The provider communication and rapport module will improve health care provider communication to address fear of side effects, concern regarding change in appearance, or side effect-related distress.
The medication routines management module will develop strategies and behaviors that help create medication adherence routines for those who have difficulties with medication routines or experience outside opposition to medications.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change in Treatment Adherence Within the Past Month as Measured by the Tablet Routines Questionnaire
Zeitfenster: baseline and 6 months
|
The minimum score is 0 and the maximum score is 100.
A higher score implies poorer treatment adherence.
|
baseline and 6 months
|
Change in Treatment Adherence Within the Past Week as Measured by the Tablet Routines Questionnaire
Zeitfenster: baseline and 6 months
|
The minimum score is 0 and the maximum score is 100.
A higher score implies poorer treatment adherence.
|
baseline and 6 months
|
Change in Treatment Adherence as Measured by the Morisky Scale
Zeitfenster: baseline and 6 months
|
The minimum score is 0 and the maximum score is 4. A higher score implies poorer treatment adherence.
|
baseline and 6 months
|
Change in Treatment Adherence Within the Past Month as Measured by the Tablet Routines Questionnaire
Zeitfenster: baseline and 3 months
|
The minimum score is 0 and the maximum score is 100.
A higher score implies poorer treatment adherence.
|
baseline and 3 months
|
Change in Treatment Adherence Within the Past Week as Measured by the Tablet Routines Questionnaire
Zeitfenster: baseline and 3 months
|
The minimum score is 0 and the maximum score is 100.
A higher score implies poorer treatment adherence.
|
baseline and 3 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change in Attitude as Measured by the Attitude Toward Mood Stabilizers Questionnaire (AMSQ)
Zeitfenster: baseline and 6 months
|
The AMSQ is a modification of the Lithium Attitudes Questionnaire.
The minimum score is 0 and the maximum score is 19.
A higher score implies a poorer attitude.
|
baseline and 6 months
|
Change in Attitude as Measured by the Rating of Medication Influences (ROMI)
Zeitfenster: baseline and 6 months
|
The minimum score is 0 and the maximum score is 10.
A higher score implies a poorer attitude.
|
baseline and 6 months
|
Change in Depression as Measured by the Hamilton Rating Scale for Depression (HAM-D)
Zeitfenster: baseline and 6 months
|
The minimum score is 0 and the maximum score is 52.
A higher score implies a worse condition.
|
baseline and 6 months
|
Change in Symptoms of Bipolar Disorder as Measured by the Young Mania Rating Scale (YMRS)
Zeitfenster: baseline and 6 months
|
The minimum score is 0 and the maximum score is 60.
A higher score implies a worse condition.
|
baseline and 6 months
|
Change in Symptoms of Bipolar Disorder as Measured by the Brief Psychiatric Rating Scale (BPRS)
Zeitfenster: baseline and 6 months
|
The minimum score is 18 and the maximum score is 126.
A higher score implies a worse condition.
|
baseline and 6 months
|
Change in Global Psychopathology as Measured by the Clinical Global Impression for Bipolar Disorder (CGI-BP)
Zeitfenster: baseline and 6 months
|
The minimum score is 1 and the maximum score is 7.
A higher score implies a worse condition.
|
baseline and 6 months
|
Change in Functional Status as Measured by the Global Assessment of Functioning (GAF) Scale
Zeitfenster: baseline and 6 months
|
The minimum score is 1 and the maximum score is 100.
A higher score implies higher functioning.
|
baseline and 6 months
|
Change in Perception of Physical Health as Measured by the 12-item Short Form Health Survey (SF-12)
Zeitfenster: baseline and 6 months
|
The minimum score is 1 and the maximum score is 99.
A higher score implies higher perceived physical health.
|
baseline and 6 months
|
Change in Perception of Mental Health as Measured by the 12-item Short Form Health Survey (SF-12)
Zeitfenster: baseline and 6 months
|
The minimum score is 1 and the maximum score is 99.
A higher score implies higher perceived mental health.
|
baseline and 6 months
|
Change in Depression as Measured by the Hamilton Rating Scale for Depression (HAM-D)
Zeitfenster: baseline and 3 months
|
The minimum score is 0 and the maximum score is 52.
A higher score implies a worse condition.
|
baseline and 3 months
|
Change in Symptoms of Bipolar Disorder as Measured by the Young Mania Rating Scale (YMRS)
Zeitfenster: baseline and 3 months
|
The minimum score is 0 and the maximum score is 60.
A higher score implies a worse condition.
|
baseline and 3 months
|
Change in Symptoms of Bipolar Disorder as Measured by the Brief Psychiatric Rating Scale (BPRS)
Zeitfenster: baseline and 3 months
|
The minimum score is 18 and the maximum score is 126.
A higher score implies a worse condition.
|
baseline and 3 months
|
Change in Global Psychopathology as Measured by the Clinical Global Impression for Bipolar Disorder (CGI-BP)
Zeitfenster: baseline and 3 months
|
The minimum score is 1 and the maximum score is 7.
A higher score implies a worse condition.
|
baseline and 3 months
|
Change in Functional Status as Measured by the Global Assessment of Functioning (GAF) Scale
Zeitfenster: baseline and 3 months
|
The minimum score is 1 and the maximum score is 100.
A higher score implies higher functioning.
|
baseline and 3 months
|
Change in Attitude as Measured by the Attitude Toward Mood Stabilizers Questionnaire (AMSQ)
Zeitfenster: baseline and 3 months
|
The AMSQ is a modification of the Lithium Attitudes Questionnaire.
The minimum score is 0 and the maximum score is 19.
A higher score implies a poorer attitude.
|
baseline and 3 months
|
Change in Attitude as Measured by the Rating of Medication Influences (ROMI)
Zeitfenster: baseline and 3 months
|
The minimum score is 0 and the maximum score is 10.
A higher score implies a poorer attitude.
|
baseline and 3 months
|
Change in Perception of Physical Health as Measured by the 12-item Short Form Health Survey (SF-12)
Zeitfenster: baseline and 3 months
|
The minimum score is 1 and the maximum score is 99.
A higher score implies higher perceived physical health.
|
baseline and 3 months
|
Change in Perception of Mental Health as Measured by the 12-item Short Form Health Survey (SF-12)
Zeitfenster: baseline and 3 months
|
The minimum score is 1 and the maximum score is 99.
A higher score implies higher perceived physical health.
|
baseline and 3 months
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- R34MH078967-02 (US NIH Stipendium/Vertrag)
- R34MH078967 (US NIH Stipendium/Vertrag)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Bipolare Störung
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SAbgeschlossenBipolar IVereinigte Staaten, Frankreich, Rumänien, Polen, Kanada, Ungarn, Japan, Korea, Republik von, Malaysia, Taiwan
-
Myriad Genetic Laboratories, Inc.University of MinnesotaAbgeschlossenMajor Depression, Bipolar I und Bipolar IIVereinigte Staaten
-
Mayo ClinicAbgeschlossenMajor Depression, Bipolar I und Bipolar IIVereinigte Staaten
-
Roxane LaboratoriesAbgeschlossenBehandlung der Bipolar-I-StörungVereinigte Staaten
-
University of Sao PauloUnbekannt
-
Mclean HospitalZurückgezogenBipolar, Manie | Bipolar, gemischter Zustand
-
Mayo ClinicAbgeschlossenDepression | Stimmungsschwankung | BipolarVereinigte Staaten
-
University of Maryland, BaltimoreNational Institute of Mental Health (NIMH)AbgeschlossenSchizophrenie | BipolarVereinigte Staaten
-
Taichung Veterans General HospitalUnbekannt
-
Korea Otsuka Pharmaceutical Co., Ltd.RekrutierungDepressionen, BipolarKorea, Republik von
Klinische Studien zur Psychoeducation module
-
Haukeland University HospitalNoch keine RekrutierungIBS – Reizdarmsyndrom
-
University of NimesNoch keine RekrutierungWohlbefinden | Emotionalen Stress | Psychosoziales Problem | Funktionsbeeinträchtigung | BenutzererfahrungFrankreich
-
Indiana UniversityAbgeschlossenRechte | Medizinrechtliche AspekteVereinigte Staaten
-
Florida International UniversityRekrutierungAngststörungenVereinigte Staaten
-
University of MinnesotaAbgeschlossenAffenpockenVereinigte Staaten
-
Assistance Publique - Hôpitaux de ParisGETAID PediatricAbgeschlossen
-
University of BaselRekrutierungAortenklappenerkrankungSchweiz
-
National Taiwan University HospitalRekrutierung
-
Eye Hospital Pristina KosovoAnmeldung auf Einladung
-
Indiana UniversityAgency for Healthcare Research and Quality (AHRQ)Abgeschlossen